Mankind Pharma Ltd announced on Wednesday that it has partnered with Denovo Sciences to launch an AI-driven drug discovery program.
Mankind Pharma said in a press release that this partnership represents a milestone in its strategy for R&D innovation driven by technology.
The partnership is aiming to achieve three main objectives: cutting early drug discovery timelines, enhancing the quality of lead candidates being developed, and filtering out the most viable potential drugs.
By introducing computational accuracy at the start of the drug development process, the two companies plan to minimise time and effort spent on drugs that have a low chance of succeeding later.
This collaboration will combine Mankind Pharma’s research & development infrastructure, experimental and clinical validation expertise with Denovo Sciences’ custom AI platform. “Together, both organisations will work under a human-in-the-loop model, where AI generates and evaluates molecular candidates while scientific experts guide, validate, and refine the results at every stage,” the statement said.
Faster discovery cycles and better candidate selection can help bring differentiated, effective, and accessible therapies to patients sooner, it added.
Arjun Juneja, Mankind Pharma’s COO stated, “Drug discovery has always been a long and uncertain journey, and that uncertainty has real consequences for patients. Our collaboration with Denovo Sciences is about using the best available technology to make this journey faster and more precise.”
He added, “AI gives us the ability to explore a much larger molecular space than traditional methods, while the human-in-the-loop model ensures that scientific rigour remains central to every decision. This is the kind of R&D investment we believe will shape Mankind Pharma’s next chapter.”
Denovo Sciences Inc CEO Hovakim Zakaryan said that collaborating with Mankind Pharma is a obvious fit for the platform that they’ve built. It is designed to work alongside experienced drug discovery experts to generate better candidates faster.
“Mankind Pharma brings deep R&D expertise and a strong commitment to making medicines more accessible. Together, we are using our proprietary AI technologies where they can create the greatest impact at the earliest stage of the discovery process, where the right decisions save the most time,” Zakaryan said.
